Analysts Set Pediatrix Medical Group, Inc. (NYSE:MD) PT at $16.67

Pediatrix Medical Group, Inc. (NYSE:MD - Get Free Report) has been given a consensus recommendation of "Hold" by the six analysts that are covering the firm, MarketBeat Ratings reports. Four analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $16.67.

MD has been the topic of several research reports. Truist Financial cut their price objective on Pediatrix Medical Group from $18.00 to $16.00 and set a "hold" rating on the stock in a research report on Friday, April 11th. Macquarie lifted their price objective on Pediatrix Medical Group from $19.00 to $20.00 and gave the company an "outperform" rating in a research report on Thursday, May 8th. Finally, UBS Group cut their price objective on Pediatrix Medical Group from $18.50 to $16.00 and set a "neutral" rating on the stock in a research report on Monday, May 12th.

Pediatrix Medical Group Trading Down 0.6%

Shares of NYSE MD traded down $0.08 during trading hours on Friday, hitting $14.15. The company's stock had a trading volume of 968,608 shares, compared to its average volume of 863,981. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.42 and a current ratio of 1.60. The stock has a market cap of $1.22 billion, a price-to-earnings ratio of -11.79, a P/E/G ratio of 1.74 and a beta of 1.26. Pediatrix Medical Group has a 12 month low of $6.62 and a 12 month high of $17.67. The business has a 50-day simple moving average of $13.72 and a 200-day simple moving average of $14.04.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported $0.33 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.25 by $0.08. The company had revenue of $458.36 million for the quarter, compared to analysts' expectations of $451.44 million. Pediatrix Medical Group had a positive return on equity of 15.47% and a negative net margin of 4.92%. Pediatrix Medical Group's quarterly revenue was down 7.4% on a year-over-year basis. During the same period last year, the firm earned $0.20 earnings per share. On average, analysts anticipate that Pediatrix Medical Group will post 1.38 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Pediatrix Medical Group

A number of hedge funds have recently added to or reduced their stakes in the stock. Strs Ohio purchased a new stake in Pediatrix Medical Group during the 1st quarter valued at $690,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Pediatrix Medical Group by 4.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 268,506 shares of the company's stock valued at $3,891,000 after buying an additional 12,171 shares during the last quarter. Optimize Financial Inc purchased a new stake in Pediatrix Medical Group during the 1st quarter valued at $167,000. Empowered Funds LLC raised its stake in Pediatrix Medical Group by 3.2% during the 1st quarter. Empowered Funds LLC now owns 289,452 shares of the company's stock valued at $4,194,000 after buying an additional 9,007 shares during the last quarter. Finally, Aristeia Capital L.L.C. purchased a new stake in Pediatrix Medical Group during the 1st quarter valued at $355,000. 97.71% of the stock is currently owned by hedge funds and other institutional investors.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.